Sarah Tegan Hogan

Sarah advises life sciences and digital health companies on structuring and negotiating complex strategic partnerships. With a scientific background and extensive private practice experience, she delivers pragmatic, business-focused solutions that foster successful, enduring partnerships. She has a deep understanding of the commercial pressures her clients face at all stages of their life cycle – whether securing funding, accelerating product development or managing regulatory risk – and helps structure deals that leverage scientific assets while preserving value and achieving business goals. Clients rely on her to anticipate friction points, protect core assets, foster collaboration across stakeholders and ensure that every agreement lays a clear, durable foundation for innovation and growth.

Sarah’s clients span the full life sciences life cycle, including early-stage startups, venture capital and private equity-backed entities, privately held businesses and public companies. Sarah regularly counsels clients on a range of complex strategic transactions, including license agreements, collaboration agreements, co-development and co-commercialization arrangements, joint ventures, spinout transactions and cross-border transactions. 

Representative matters

Sarah has recently represented: 

• A biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases in its $1.2 billion exclusive option and license agreement for rights to a deep-brain penetrating adeno-associated virus (AAV) capsid for vectorized antibody payloads against three therapeutic targets (2025)*

• A biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic disease in its out-license of rights to its monoclonal antibody therapy to a Japanese specialty pharmaceutical company (2025)*

• A multinational pharmaceutical company in its $5.3 billion exclusive worldwide collaboration and license agreement with a biotechnology company to co-develop and co-commercialize a foundational therapy for overweight and obesity patients (2025)*

• A biotechnology company advancing molecular glue discovery with rational selection and design in its $1.25 billion exclusive worldwide collaboration and license agreement with a multinational pharmaceutical company to discover, develop and commercialize molecular glue therapeutics in oncology (2025)*

• A biotechnology company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring in its exclusive worldwide license and collaboration agreement with a multinational pharmaceutical company for the development of a radiotherapeutic candidate for cancer (2024)*

• A clinical-stage biopharmaceutical company dedicated to advancing novel neuropsychiatric medicines in its spinoff from a biotherapeutics company and $100 million Series A financing round (2024)*

• A next-generation gene-editing company developing potentially curative therapeutics for patients with serious diseases based on its proprietary and modular toolbox of DNA-editing technologies in its strategic partnership focused on advancing new AAV-based gene-editing therapies for central nervous system diseases with high unmet medical needs (2024)*

• A biotechnology company dedicated to advancing neurogenetic medicines in its strategic collaboration agreement with a neuroscience-focused biopharmaceutical company to advance multiple gene therapies for the treatment of neurological diseases (2024)*

• A clinical-stage biotechnology company in its research collaboration with a pharmaceutical company focused on advancing the company’s preclinical stage in vivo gene-editing program targeting a lipoprotein (2023)*

• A biotechnology company dedicated to breaking through barriers in gene therapy and neurology in its $1.5 million strategic collaboration to advance multiple gene therapies for the treatment of neurological diseases (2023)*

• A biopharmaceutical company focused on developing life-changing therapies for allergic and immunological disease in its worldwide exclusive license agreement for monoclonal antibodies for treatment of atopic dermatitis and other allergic and immunological diseases (2023)*

• A gene-editing company in its strategic research collaboration and nonexclusive license agreement focused on development of allogeneic cell therapies and its worldwide nonexclusive license agreement with a clinical-stage global biotechnology company to advance engineered cell therapy programs in oncology (2022)*

• A biotechnology company developing precision genetic medicines through base editing in its $1.35 billion multitarget research collaboration, co-development and co-commercialization agreement with a global pharmaceutical company (2022)*

• A preclinical contract research organization in a multiyear strategic partnership with a biotechnology company to offer a transformative, AI-enabled drug discovery and development platform (2022)*

• A clinical-stage genetic medicine company in its global research collaboration focused on discovering and developing in vivo gene-editing therapy for liver disease (2022)*

• A gene-editing company in its $1.2 billion collaboration to enhance development of ex vivo engineered cell therapies (2021)*

• A clinical-stage biopharmaceutical company in its $1.25 billion strategic collaboration with a global biopharmaceutical company to accelerate the advancement of a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need (2020)*

• A conversational AI and ambient intelligence technology company in its strategic partnership with a global technology company aimed at accelerating the delivery of ambient clinical intelligence (ACI) technologies to reduce clinician burnout (2019)*

• A French biotech company focused on developing virus-based immunotherapies for cancer and infectious diseases in its strategic collaboration with a global biopharmaceutical company to develop innovative oncolytic virus immunotherapies (2019)*

* Representation handled before joining Cooley